Classification of Farnsworth-Munsell 100-hue Test Results in the Early Treatment Diabetic Retinopathy Study
Overview
Affiliations
Purpose: To classify and describe clinically meaningful classes of color vision defects using pretreatment Farnsworth-Munsell 100-hue results from the Early Treatment Diabetic Retinopathy Study (ETDRS) patients using standard statistical techniques.
Design: The ETDRS was a randomized trial investigating retinal photocoagulation and oral aspirin in diabetic retinopathy.
Methods: Farnsworth-Munsell (FM) 100-hue test was successfully administered before initiation of study treatment in each eye of 2701 of the 3711 ETDRS patients. Test results were converted into a Fourier series, classified by cluster analysis in the deferred-treatment group of eyes, and verified in the immediate-treatment group of eyes as separate samples.
Results: Cluster analysis uncovered thirteen distinct patterns. Pattern A (51% or 1366 of the eyes) showed unimpaired hue discrimination and was comprised of younger patients with no or little macular edema. Pattern B eyes (10% or 262) showed generalized impairment of hue discrimination with no main axis defect. Patterns C (C1, C2, C3), comprising 26% (or 698) of the eyes, showed increasing severity of the yellow-blue diabetic retinopathy defect, associated with increasing mean age and increasing macular edema severity. Patterns D (D1, D2), comprising 6% (or 164) of the eyes, were similar to the C patterns but showed a stronger yellow-blue defect. Patterns E (E1, E2, E3), or approximately 2% (or 38) of the eyes and predominantly male, exhibited the expected pattern for congenital protan defect. Patterns F, G, and H, approximately 6% (or 153) of the eyes, showed distinct patterns of one-sided axes. The nomenclature is arbitrary.
Conclusions: Cluster analysis of FM 100-hue test results has found 13 patterns of impaired hue discrimination, helpful in understanding color vision defects in diabetes mellitus.
Orduna-Hospital E, Arcas-Carbonell M, Sanchez-Cano A, Pinilla I, Consejo A J Pers Med. 2022; 12(11).
PMID: 36579516 PMC: 9693211. DOI: 10.3390/jpm12111807.
Orduna-Hospital E, Sanchez-Cano A, Perdices L, Acha J, Lopez-Alaminos E, Pinilla I Sci Rep. 2021; 11(1):10427.
PMID: 34001996 PMC: 8129145. DOI: 10.1038/s41598-021-89992-w.
New iPAD-based test for the detection of color vision deficiencies.
de Fez D, Luque M, Matea L, Pinero D, Camps V Graefes Arch Clin Exp Ophthalmol. 2018; 256(12):2349-2360.
PMID: 30291435 DOI: 10.1007/s00417-018-4154-y.
Abdel-Hay A, Sivaprasad S, Subramanian A, Barbur J PLoS One. 2018; 13(6):e0199693.
PMID: 29944702 PMC: 6019681. DOI: 10.1371/journal.pone.0199693.
Gella L, Raman R, Kulothungan V, Pal S, Ganesan S, Srinivasan S Indian J Ophthalmol. 2017; 65(10):989-994.
PMID: 29044066 PMC: 5678337. DOI: 10.4103/ijo.IJO_601_16.